Adult phenylketonuria outcome and management (Q37938198)

25 August 2017

1 reference

title

Adult phenylketonuria outcome and management (English)

1 reference

25 August 2017

1 reference

F Trefz

1

1 reference

25 August 2017

F Maillot

series ordinal

2

1 reference

25 August 2017

K Motzfeldt

series ordinal

3

1 reference

25 August 2017

M Schwarz

series ordinal

4

1 reference

25 August 2017

language of work or name

1 reference

26 August 2011

1 reference

Molecular Genetics and Metabolism

25 August 2017

published in

1 reference

25 August 2017

volume

104 Suppl

1 reference

25 August 2017

page(s)

S26-30

1 reference

Challenges and pitfalls in the management of phenylketonuria

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Final intelligence in late treated patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Late-treated phenylketonuria and partial reversibility of intellectual impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Phenylketonuria in adulthood: a collaborative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Frontal lobe-dependent functions in treated phenylketonuria: blood phenylalanine concentrations and long-term deficits in adolescents and young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Effects of dietary management of phenylketonuria on long-term cognitive outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

The intake of total protein, natural protein and protein substitute and growth of height and head circumference in Dutch infants with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

The use of prealbumin concentration as a biomarker of nutritional status in treated phenylketonuric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Peak bone mass in patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Impact of metabolic control on bone quality in phenylketonuria and mild hyperphenylalaninemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Serum vitamin B12 concentrations within reference values do not exclude functional vitamin B12 deficiency in PKU patients of various ages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Stability of blood phenylalanine levels and IQ in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Global and regional volume changes in the brains of patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

MRI abnormalities in normal-appearing brain tissue of treated adult PKU patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

White matter pathology in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Reduced cerebral fluoro-L-dopamine uptake in adult patients suffering from phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Blood phenylalanine control in adolescents with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.08.025

10.1016/J.YMGME.2011.08.025

7 January 2021

Identifiers

DOI

1 reference

25 August 2017

1 reference